Spring Bank Pharmaceuticals, Inc. (SBPH): Price and Financial Metrics


Spring Bank Pharmaceuticals, Inc. (SBPH)

Today's Latest Price: $1.45 USD

0.01 (-0.68%)

Updated Jul 2 3:59pm

Add SBPH to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 214 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

SBPH Daily Price Range
SBPH 52-Week Price Range

SBPH Stock Price Chart Technical Analysis Charts


SBPH Price/Volume Stats

Current price $1.45 52-week high $5.70
Prev. close $1.46 52-week low $0.80
Day low $1.45 Volume 29,802
Day high $1.52 Avg. volume 181,940
50-day MA $1.54 Dividend yield N/A
200-day MA $2.04 Market Cap 24.79M

Spring Bank Pharmaceuticals, Inc. (SBPH) Company Bio


Spring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of a class of therapeutics using its proprietary small molecule nucleic acid hybrid (SMNH) chemistry platform. The company was founded in 2002 and is based in Milford, Massachusetts


SBPH Latest News Stream


Event/TimeNews Detail
Loading, please wait...

SBPH Latest Social Stream


Loading social stream, please wait...

View Full SBPH Social Stream

Latest SBPH News From Around the Web

Below are the latest news stories about Spring Bank Pharmaceuticals Inc that investors may wish to consider to help them evaluate SBPH as an investment opportunity.

Hedge Funds Are Selling Spring Bank Pharmaceuticals, Inc. (SBPH)

In this article we will check out the progression of hedge fund sentiment towards Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH) and determine whether it is a good investment right now. We at Insider Monkey like to examine what billionaires and hedge funds think of a company before spending days of research on it. Given their 2 […]

Yahoo | June 5, 2020

Spring Bank Pharmaceuticals (SBPH) Investor Presentation - Slideshow

The following slide deck was published by Spring Bank Pharmaceuticals, Inc. in conjunction with this event....

SA Transcripts | June 3, 2020

Spring Bank Advances IV SB 11285 Clinical Program

Spring Bank Pharmaceuticals, Inc. (SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology and inflammatory diseases, today announced that its Phase 1a/1b clinical trial of the company’s intravenously (IV)-administered STING agonist, SB 11285, continues to advance to an escalated monotherapy dosing level and the first cohort in which patients in the trial will receive the co-administration of the IV STING agonist and a checkpoint inhibitor. This Phase 1a/1b trial has been able to progress on track even in the midst of challenges posed by the COVID-19 pandemic.

Yahoo | June 3, 2020

Spring Bank to Present at the Jefferies Virtual Global Healthcare Conference

HOPKINTON, Mass., May 26, 2020 -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment.

Yahoo | May 26, 2020

Spring Bank Announces Poster Presentation at the 2020 American Society of Clinical Oncology (ASCO) Virtual Annual Meeting

HOPKINTON, Mass., May 20, 2020 -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment.

Yahoo | May 20, 2020

Read More 'SBPH' Stories Here

SBPH Price Returns

1-mo -13.69%
3-mo 64.79%
6-mo 0.00%
1-year -71.17%
3-year -90.95%
5-year N/A
YTD -8.23%
2019 -84.79%
2018 -22.69%
2017 68.21%
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.7965 seconds.